Dobecure

Executive Summary

Dobecure is a private Spanish biotechnology company founded in 2018 and headquartered in Barcelona. Its stated focus is on developing digital therapeutics and software solutions for chronic disease management and patient monitoring, although it is categorized within the broader cell and gene therapy sector. The company's exact therapeutic areas and technology platform remain unclear due to limited public information. As of early 2026, Dobecure has not disclosed any funding rounds, pipeline candidates, or clinical stage assets, making it an early-stage entity with a highly opaque profile. The company's website and available databases provide minimal detail on its operations, partnerships, or scientific approach. Given the lack of transparency and absence of disclosed milestones, Dobecure appears to be in a very early or stealth phase, with no confirmed revenue, product, or regulatory progress. The company's classification under cell & gene therapy may be a miscategorization, as its description emphasizes software-based interventions rather than biological therapies. Investors should approach with extreme caution and seek further clarification before considering any engagement.